June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Predicting Surgical Interventions for Glaucoma with Clinically Available Data
Author Affiliations & Notes
  • Ruben Gonzalez
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Justin Huynh
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Evan Walker
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Bharanidharan Radha Saseendrakumar
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Christopher Bowd
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Akram Belghith
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Michael Henry Goldbaum
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Massimo Antonio Fazio
    Department of Ophthalmology and Vision Sciences, Heersink School of Medicine, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, United States
  • Christopher A Girkin
    Department of Ophthalmology and Vision Sciences, Heersink School of Medicine, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, United States
  • Gustavo De Moraes
    Bernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, New York, United States
  • Jeffrey M Liebmann
    Bernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, New York, United States
  • Robert Weinreb
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Sally L. Baxter
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Linda M Zangwill
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Mark Christopher
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Footnotes
    Commercial Relationships   Ruben Gonzalez None; Justin Huynh None; Evan Walker None; Bharanidharan Saseendrakumar None; Christopher Bowd None; Akram Belghith None; Michael Goldbaum None; Massimo Fazio National Eye Institute, EyeSight Foundation of Alabama, Research to Prevent Blindness, Heidelberg Engineering, GmbH, Topcon and Wolfram Research, Code F (Financial Support); Christopher Girkin National Eye Institute, Heidelberg Engineering, Topcon, EyeSight Foundation of Alabama, Research to Prevent Blindness, GmbH, Code F (Financial Support); Gustavo De Moraes Novartis, Galimedix, Belite, Reichert, Carl Zeiss, Perfuse Therapeutics, Code C (Consultant/Contractor), Ora Clinical, Code E (Employment), Heidelberg, Topcon, Code R (Recipient); Jeffrey Liebmann Allergan, Genentech, Thea, Bausch & Lomb, Code C (Consultant/Contractor), Novartis, Research to Prevent Blindness, Code F (Financial Support); Robert Weinreb Abbvie, Aerie Pharmaceuticals, Allergan, Equinox, Iantrek, Implandata, Nicox, Topcon Medical , Code C (Consultant/Contractor), Bausch & Lomb, Topcon Medical, Heidelberg Engineering, Carl Zeiss Meditec, Optovue, Centervue , Code F (Financial Support), Toromedes, Carl Zeiss Meditec, Code P (Patent); Sally Baxter voxelcloud.io, Code C (Consultant/Contractor), Optomed, Topcon, Code F (Financial Support), iVista Medical Education, Code I (Personal Financial Interest); Linda Zangwill Abbvie Inc., Topcon, Code C (Consultant/Contractor), National Eye Institute, Carl Zeiss Meditec Inc., Heidelberg Engineering GmbH, Optovue Inc., Topcon Medical Systems Inc., Code F (Financial Support), Zeiss Meditec, AISight Health, Code P (Patent); Mark Christopher AISight Health, Code P (Patent)
  • Footnotes
    Support  This work is supported by National Institutes of Health/National Eye Institute Grants (R41EY034424, R01EY034146, R01EY029058, R01EY11008, R01EY19869, R01EY027510, R01EY026574, EY018926, K99EY030942, P30EY022589) and an unrestricted grant from Research to Prevent Blindness (New York, NY). The Glaucoma Foundation. The sponsor or funding organization had no role in the design or conduct of this research.
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 387. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ruben Gonzalez, Justin Huynh, Evan Walker, Bharanidharan Radha Saseendrakumar, Christopher Bowd, Akram Belghith, Michael Henry Goldbaum, Massimo Antonio Fazio, Christopher A Girkin, Gustavo De Moraes, Jeffrey M Liebmann, Robert Weinreb, Sally L. Baxter, Linda M Zangwill, Mark Christopher; Predicting Surgical Interventions for Glaucoma with Clinically Available Data. Invest. Ophthalmol. Vis. Sci. 2023;64(8):387.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the accuracy of using patient demographics, clinical measurements, optical coherence tomography (OCT), and visual field (VF) testing in machine learning (ML) models to predict the need for surgical intervention for glaucoma within the next 12 months, 2 years, and 3 years.

Methods : Data collected from participants of the Diagnostic Innovations in Glaucoma Study and the African Descent and Glaucoma Evaluation Study were used to build and evaluate ML models predicting glaucoma surgery. For training, 369 glaucoma surgery cases were identified based on self-reported glaucoma-related ocular surgeries. Sample sizes of non-surgery controls varied with time horizon between 587–592. For modeling, data consisted of demographics (age, sex, race), medication and systemic medical condition (hypertension, diabetes) history, ophthalmic measurements (IOP, CCT, spherical equivalent, axial length) along with 24-2 VF results, and Heidelberg Spectralis RNFL thickness measurements. To predict glaucoma surgery at each time horizon (12 months, 2 years, and 3 years), measurements prior to that time period were included in the modeling. Finally, models were evaluated using area under the ROC-curve, precision, recall, and F1 score on a holdout set of participants from an independent study site. The algorithms tested include random forests, gradient boosting machines, and generalized linear models.

Results : Results for our highest performing models in predicting glaucoma surgical intervention are shown in Table 1. The best performing model was a gradient boosting machine. These models achieved AUC scores of 0.88, 0.91, and 0.91 and precision scores of 0.85, 0.87, and 0.86 at 12 months, 2 years, and 3 years, respectively.

Conclusions : Machine learning models trained on clinical data were able to predict surgical interventions with high accuracy up to three years prior to surgery. Future work will also incorporate full OCT imaging data to improve model predictions. These approaches could provide clinicians with an important tool to predict the need for glaucoma interventions and preserve vision.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

Table 1. Overview of models predicting surgical intervention at different time horizons.

Table 1. Overview of models predicting surgical intervention at different time horizons.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×